{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:20:26Z","timestamp":1773832826924,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cca.2023.117514","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T11:13:35Z","timestamp":1691579615000},"page":"117514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparison of performance and clinical utility of different methods for detecting anti-PLA2R antibody"],"prefix":"10.1016","volume":"548","author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huangmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanzheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cca.2023.117514_b0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy\u2013a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"Suppl 1","key":"10.1016\/j.cca.2023.117514_b0010","first-page":"64","article-title":"Secondary membranous glomerulonephritis","volume":"7","author":"Glassock","year":"1992","journal-title":"Nephrol. Dial Transplant."},{"issue":"1","key":"10.1016\/j.cca.2023.117514_b0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.cca.2023.117514_b0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-020117-043811","article-title":"Molecular Pathogenesis of Membranous Nephropathy","volume":"15","author":"Ronco","year":"2020","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.cca.2023.117514_b0025","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S)."},{"issue":"6","key":"10.1016\/j.cca.2023.117514_b0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40620-018-0533-z","article-title":"Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy","volume":"31","author":"Tampoia","year":"2018","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.cca.2023.117514_b0035","first-page":"109","article-title":"Anti-PLA\u2082R antibodies in membranous nephropathy: ready for routine clinical practice?","volume":"70","author":"Hofstra","year":"2012","journal-title":"Neth J. Med."},{"key":"10.1016\/j.cca.2023.117514_b0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jim.2017.02.001","article-title":"Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy","volume":"444","author":"Burbelo","year":"2017","journal-title":"J. Immunol. Methods."},{"issue":"6","key":"10.1016\/j.cca.2023.117514_b0045","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/ac802267u","article-title":"Quantitative detection of HIV-1 particles using HIV-1 neutralizing antibody-conjugated beads","volume":"81","author":"Kim","year":"2009","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2023.117514_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112913","article-title":"Development of magnetic particle-based chemiluminescence immunoassay for measurement of human procalcitonin in serum","volume":"488","author":"Liao","year":"2021","journal-title":"J. Immunol. Methods."},{"issue":"3","key":"10.1016\/j.cca.2023.117514_b0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpha.2011.06.004","article-title":"Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3","volume":"1","author":"Zhang","year":"2011","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.cca.2023.117514_b0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.aca.2013.09.050","article-title":"Magnetic-particle-based, ultrasensitive chemiluminescence enzyme immunoassay for free prostate-specific antigen","volume":"801","author":"Liu","year":"2013","journal-title":"Anal. Chim. Acta."},{"issue":"1","key":"10.1016\/j.cca.2023.117514_b0065","doi-asserted-by":"crossref","first-page":"8778","DOI":"10.1038\/s41598-021-88343-z","article-title":"Rapid, quantitative, and high-sensitivity detection of anti-phospholipase A2 receptor antibodies using a novel CdSe\/ZnS-based fluorescence immunosorbent assay","volume":"11","author":"Li","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.cca.2023.117514_b0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ekir.2019.11.008","article-title":"Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy","volume":"5","author":"D\u00e4hnrich","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.cca.2023.117514_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108729","article-title":"Comparison of 3 anti-PLA2R inmmunoassaysfor the diagnosis of idiopathic membranous nephropathy in an european population A pilot study","volume":"227","author":"Nieto-Ga\u00f1\u00e1n","year":"2021","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.cca.2023.117514_b0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40620-020-00888-w","article-title":"Diagnostic accuracy of anti-phospholipase A2 receptor (PLA2R) antibodies in idiopathic membranous nephropathy: an Italian experience","volume":"34","author":"Porcelli","year":"2021","journal-title":"J. Nephrol."},{"issue":"1","key":"10.1016\/j.cca.2023.117514_b0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3904\/kjim.2020.366","article-title":"The optimal anti-phospholipase A2 receptor cutoff for the diagnosis of idiopathic membranous nephropathy: a single-center retrospective study","volume":"37","author":"Li","year":"2022","journal-title":"Korean J. Intern. Med."},{"issue":"6","key":"10.1016\/j.cca.2023.117514_b0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11255-016-1263-6","article-title":"The accuracy of the anti-phospholipase A2 receptor antibody in the diagnosis of idiopathic membranous nephropathy: a comparison of different cutoff values as measured by the ELISA method","volume":"48","author":"Dou","year":"2016","journal-title":"Int. Urol. Nephrol."},{"issue":"3","key":"10.1016\/j.cca.2023.117514_b0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pathol.2016.02.001","article-title":"Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis","volume":"48","author":"Ong","year":"2016","journal-title":"Pathology"},{"issue":"8","key":"10.1016\/j.cca.2023.117514_b0100","doi-asserted-by":"crossref","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2023.117514_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2017.11.006","article-title":"Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients","volume":"476","author":"Liu","year":"2018","journal-title":"Clin. Chim. Acta."},{"issue":"2\u20133","key":"10.1016\/j.cca.2023.117514_b0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000521836","article-title":"Optimal Value for Serum Anti-PLA2R Antibody in Primary Membranous Nephropathy: A Multicenter Observational Study","volume":"53","author":"Chen","year":"2022","journal-title":"Am. J. Nephrol."},{"issue":"3","key":"10.1016\/j.cca.2023.117514_b0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000440983","article-title":"Anti-Phospholipase A2 Receptor Antibody as Prognostic Indicator in Idiopathic Membranous Nephropathy","volume":"42","author":"Kim","year":"2015","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.cca.2023.117514_b0120","doi-asserted-by":"crossref","unstructured":"Logt A-Evd, Justino J, Vink CH, van den Brand J, Debiec H, Lambeau G, et al. Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy. Kidney Int. Rep. 2021;6(6):1677\u20131686.","DOI":"10.1016\/j.ekir.2021.04.002"},{"issue":"5","key":"10.1016\/j.cca.2023.117514_b0125","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.cca.2023.117514_b0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.cca.2023.117514_b0135","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cca.2023.117514_b0140","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New 'Antigens' in Membranous Nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123003169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123003169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:13:05Z","timestamp":1757862785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123003169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S0009898123003169"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117514","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of performance and clinical utility of different methods for detecting anti-PLA2R antibody","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117514"}}